Breast cancer

NICE recommends olaparib for advanced breast cancer in final draft guidance

The drug has previously been recommended for some types of ovarian cancer in England and for prostate cancer in Scotland.…

MHRA approves capivasertib for treatment of advanced breast cancer

Capivasertib is an oral pill given with fulvestrant, a hormonal therapy, as an alternative treatment to endocrine-based regimens.…

Cannabidiol as a chemotherapy adjunct in cancer treatment

An overview of the potential of cannabidiol in combination with standard chemotherapy drugs for both the treatment of cancer and management of chemotherapy side effects.…

Medicines regulator approves anastrozole for prevention of breast cancer in post-menopausal women

NHS England says around 289,000 women at moderate or high risk of breast cancer could benefit from anastrozole.…

Thousands of NHS patients with prostate or breast cancer eligible for new targeted treatment

NHS England says around 800 people in England could be eligible for olaparib treatment each year.…

Don’t dismiss fears over switching generics, take it from two cancer ‘thrivers’

Ruth Edwards and Avril Chester share their experience of the impact medicines shortages can have on people who rely on long-term medicines after cancer treatment.…

The role of circulating tumour DNA in guiding cancer treatment and future applications

An overview of current and future applications of circulating tumour DNA in common solid tumours and the implications on treatment.…

New estimates for breast cancer risk associated with HRT

New estimates of the increased risks of breast cancer associated with use of different hormone replacement therapy preparations have been published in the BMJ.…

Five years on: what my experience with breast cancer taught me about good patient care

Ruth Edwards reflects on her experience as a patient with breast cancer and how it taught her a valuable lesson about patient care.…

Addition of abemaciclib to hormonal therapy for high-risk early breast cancer reduces recurrence by 25%, research suggests

Combining abemaciclib with hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer, interim analysis of a phase III study has suggested.…